eFFECTOR Therapeutics (NASDAQ:EFTR) and Synaptogenix (NASDAQ:TAOX) Head to Head Review

Synaptogenix (NASDAQ:TAOX) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap manufacturing companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Earnings & Valuation

This table compares Synaptogenix and eFFECTOR Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	N/A	N/A	-$12.77 million	($20.16)	-0.24
eFFECTOR Therapeutics	N/A	N/A	-$35.81 million	($13.08)	0.00

Synaptogenix is trading at a lower price-to-earnings ratio than eFFECTOR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Synaptogenix and eFFECTOR Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1	0	0	0	1.00
eFFECTOR Therapeutics	0	0	0	0	0.00

Volatility and Risk

Synaptogenix has a beta of 1.94, indicating that its stock price is 94% more volatile than the S&P 500. Comparatively, eFFECTOR Therapeutics has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500.

Profitability

This table compares Synaptogenix and eFFECTOR Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Synaptogenix	N/A	-240.92%	-150.03%
eFFECTOR Therapeutics	N/A	N/A	N/A

Insider and Institutional Ownership

10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

eFFECTOR Therapeutics beats Synaptogenix on 6 of the 9 factors compared between the two stocks.

About Synaptogenix

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

About eFFECTOR Therapeutics

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.